Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34


Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

Shao Z, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang YC, Wang H, Kang SY, Seo JH, Shen K, Laohawiriyakamol S, Jiang Z, Li J, Zhou J, Althaus B, Mao Y, Eng-Wong J.

JAMA Oncol. 2019 Oct 24. doi: 10.1001/jamaoncol.2019.3692. [Epub ahead of print]


Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.

Kirschbrown WP, Wynne C, Kågedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A.

J Clin Pharmacol. 2019 May;59(5):702-716. doi: 10.1002/jcph.1362. Epub 2018 Dec 19.


Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK.

Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11.


Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group.

Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773.


Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J.

Eur J Cancer. 2018 Jan;89:27-35. doi: 10.1016/j.ejca.2017.10.021. Epub 2017 Dec 8.


Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.

Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, Láng I, Tomasello G, Douthwaite H, Badovinac Crnjevic T, Heeson S, Eng-Wong J, Muñoz M.

J Clin Oncol. 2017 Sep 10;35(26):3030-3038. doi: 10.1200/JCO.2016.70.6267. Epub 2017 Apr 24.


Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.

Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L.

Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9.


Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S.

Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.


Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.

Gatti-Mays ME, Venzon D, Galbo CE, Singer A, Reynolds J, Makariou E, Kallakury B, Heckman-Stoddard BM, Korde L, Isaacs C, Warren R, Gallagher A, Eng-Wong J.

Cancer Prev Res (Phila). 2016 Mar;9(3):225-33. doi: 10.1158/1940-6207.CAPR-15-0269. Epub 2016 Jan 12.


Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.

Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML.

Breast Cancer Res. 2014;16(4):424. doi: 10.1186/PREACCEPT-1744229618121391. Epub 2014 Aug 23.


Promoting mammography adherence in underserved women: the telephone coaching adherence study.

Sheppard VB, Huei-yu Wang J, Eng-Wong J, Martin SH, Hurtado-de-Mendoza A, Luta G.

Contemp Clin Trials. 2013 May;35(1):35-42. doi: 10.1016/j.cct.2013.02.005. Epub 2013 Feb 13.


Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia.

Hoffman HJ, LaVerda NL, Young HA, Levine PH, Alexander LM, Brem R, Caicedo L, Eng-Wong J, Frederick W, Funderburk W, Huerta E, Swain S, Patierno SR.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1655-63. doi: 10.1158/1055-9965.EPI-12-0479.


Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women.

Mays D, Sharff ME, DeMarco TA, Williams B, Beck B, Sheppard VB, Peshkin BN, Eng-Wong J, Tercyak KP.

Fam Cancer. 2012 Sep;11(3):493-502. doi: 10.1007/s10689-012-9541-7.


The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.

Shanmugam VK, McCloskey J, Elston B, Allison SJ, Eng-Wong J.

Breast Cancer Res Treat. 2012 Jan;131(2):699-708. doi: 10.1007/s10549-011-1849-8. Epub 2011 Nov 11.


Triple negative breast cancer: breast cancer research in evolution.

Eng-Wong J, Hunsberger S, Zujewski JA.

Breast Dis. 2010;32(1-2):1-4. doi: 10.3233/BD-2010-0314. No abstract available.


Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.

Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, Warren R, Eng-Wong J, Cohen P, Smith KL, Creswell K, Novielli A, Slack R.

Breast Cancer Res Treat. 2011 Jan;125(1):137-43. doi: 10.1007/s10549-010-1226-z. Epub 2010 Oct 26.


The impact of systemic therapy following ductal carcinoma in situ.

Eng-Wong J, Costantino JP, Swain SM.

J Natl Cancer Inst Monogr. 2010;2010(41):200-3. doi: 10.1093/jncimonographs/lgq021. Review.


Prediction of benefit from adjuvant treatment in patients with breast cancer.

Eng-Wong J, Isaacs C.

Clin Breast Cancer. 2010;10 Suppl 1:E32-7. doi: 10.3816/CBC.2010.s.005.


Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer.

Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH.

Breast Cancer Res Treat. 2010 Aug;123(1):245-55. doi: 10.1007/s10549-010-0749-7. Epub 2010 Feb 4.


Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C.

J Clin Oncol. 2009 Nov 1;27(31):5153-9. doi: 10.1200/JCO.2008.20.6664. Epub 2009 Sep 14.


Premenopausal breast cancer: estrogen receptor status and insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-3 (IGFBP-3), and leptin.

Eng-Wong J, Perkins SN, Bondy M, Li D, Eva Singletary S, Núñez N, Hursting S, Chang S.

Breast J. 2009 Jul-Aug;15(4):426-8. doi: 10.1111/j.1524-4741.2009.00753.x. No abstract available.


Recruitment to a physical activity intervention study in women at increased risk of breast cancer.

Korde LA, Micheli A, Smith AW, Venzon D, Prindiville SA, Drinkard B, Sebring N, Smith MD, Zujewski JA, Eng-Wong J.

BMC Med Res Methodol. 2009 Apr 27;9:27. doi: 10.1186/1471-2288-9-27.


Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.

Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, Zujewski JA, Prindiville S.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1696-701. doi: 10.1158/1055-9965.EPI-07-2752. Epub 2008 Jun 26.


Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer.

Eng-Wong J, Zujewski JA.

Cancer. 2008 Feb 1;112(3 Suppl):723-729. doi: 10.1002/cncr.23188.


Gynecologic and hormonal effects of raloxifene in premenopausal women.

Premkumar A, Venzon DJ, Avila N, Johnson DV, Remaley AT, Forman MR, Eng-Wong J, Zujewski J, Stratton P.

Fertil Steril. 2007 Dec;88(6):1637-44. Epub 2007 Jul 26.


Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.

Chatterton RT Jr, Zujewski J, Mateo ET, Eng-Wong J, Jordan VC.

J Endocrinol. 2006 Dec;191(3):599-604.


Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.

Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, Liu ET, Chow C, Zujewski J.

J Clin Endocrinol Metab. 2006 Oct;91(10):3941-6. Epub 2006 Jul 25.


Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.

Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1153-8.


Sentinel lymph node biopsy in the management of ductal carcinoma in situ.

Zujewski J, Eng-Wong J.

Clin Breast Cancer. 2005 Aug;6(3):216-22. Review.


A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.

Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash N, Chow C, Clark G, Gantz SB, Venzon D, Zujewski J.

Clin Cancer Res. 2005 Feb 1;11(3):1247-52.


A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.

Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J.

Clin Cancer Res. 2004 Oct 15;10(20):6764-9.


Raloxifene and its role in breast cancer prevention.

Eng-Wong J, Zujewski JA.

Expert Rev Anticancer Ther. 2004 Aug;4(4):523-32. Review.


A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.

Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH.

Breast Cancer Res Treat. 2003 Sep;81(1):41-51.


Supplemental Content

Loading ...
Support Center